The University of Chicago Header Logo

Connection

Harvey M. Golomb to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Harvey M. Golomb has written about Lung Neoplasms.
Harvey M. Golomb
Connection Strength
1.468
Lung Neoplasms
  1. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
    View in: PubMed
    Score: 0.064
  2. Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. Semin Oncol. 1998 Feb; 25(1 Suppl 2):19-22.
    View in: PubMed
    Score: 0.061
  3. Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-67-S12-69.
    View in: PubMed
    Score: 0.059
  4. Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Semin Oncol. 1997 Aug; 24(4 Suppl 14):S14-26-S14-29.
    View in: PubMed
    Score: 0.059
  5. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
    View in: PubMed
    Score: 0.054
  6. Management of pulmonary metastases. Lancet. 1995 Jul 08; 346(8967):68.
    View in: PubMed
    Score: 0.051
  7. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. Semin Oncol. 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4.
    View in: PubMed
    Score: 0.048
  8. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
    View in: PubMed
    Score: 0.046
  9. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
    View in: PubMed
    Score: 0.042
  10. Role of systemic therapy in advanced non-small-cell lung cancer. Am J Med. 1990 Dec; 89(6):777-86.
    View in: PubMed
    Score: 0.037
  11. 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
    View in: PubMed
    Score: 0.036
  12. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
    View in: PubMed
    Score: 0.036
  13. Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer. Cancer. 1989 Oct 01; 64(7):1404-8.
    View in: PubMed
    Score: 0.034
  14. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
    View in: PubMed
    Score: 0.034
  15. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer. 1989 Jan 15; 63(2):238-42.
    View in: PubMed
    Score: 0.033
  16. Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role. Cancer. 1987 Jun 15; 59(12):2016-9.
    View in: PubMed
    Score: 0.029
  17. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep. 1987 Mar; 71(3):311-2.
    View in: PubMed
    Score: 0.029
  18. A 10-year experience with combined modality therapy for stage III small cell lung carcinoma. Cancer. 1986 Nov 15; 58(10):2177-84.
    View in: PubMed
    Score: 0.028
  19. Postoperative recurrence of lung cancer: detection by whole-body gallium scintigraphy. AJR Am J Roentgenol. 1986 Nov; 147(5):911-5.
    View in: PubMed
    Score: 0.028
  20. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy. Surgery. 1986 Oct; 100(4):621-8.
    View in: PubMed
    Score: 0.028
  21. Local recurrence of resectable non-oat cell carcinoma of the lung. A warning against conservative treatment for N0 and N1 disease. Cancer. 1986 Feb 01; 57(3):471-6.
    View in: PubMed
    Score: 0.027
  22. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg. 1985 Mar; 89(3):378-85.
    View in: PubMed
    Score: 0.025
  23. Current concepts in small cell carcinoma of the lung. CA Cancer J Clin. 1984 Sep-Oct; 34(5):269-81.
    View in: PubMed
    Score: 0.024
  24. Lack of efficacy of vinblastine and cisplatin in patients with progressive small cell carcinoma of the lung. Cancer Treat Rep. 1983 Sep; 67(9):831-2.
    View in: PubMed
    Score: 0.022
  25. Non-small cell carcinoma of the lung. Semin Oncol. 1983 Mar; 10(1):1-122.
    View in: PubMed
    Score: 0.022
  26. Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol. 1983 Mar; 10(1):111-22.
    View in: PubMed
    Score: 0.022
  27. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 2001; 19(4):329-33.
    View in: PubMed
    Score: 0.019
  28. Lung cancer: A combined modality approach to staging and therapy. CA Cancer J Clin. 1979 Sep-Oct; 29(5):258-75.
    View in: PubMed
    Score: 0.017
  29. Small-cell carcinoma of the lung: the prognostic significance of stage on survival. Eur J Cancer (1965). 1979 Jun; 15(6):859-65.
    View in: PubMed
    Score: 0.017
  30. Gallium 67 scans in small cell carcinoma. JAMA. 1979 Mar 16; 241(11):1106.
    View in: PubMed
    Score: 0.016
  31. Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15; 240(25):2743-6.
    View in: PubMed
    Score: 0.016
  32. Small-cell carcinoma of the lung. Ann Intern Med. 1978 Jul; 89(1):139.
    View in: PubMed
    Score: 0.016
  33. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann Oncol. 1998 Jun; 9(6):677-80.
    View in: PubMed
    Score: 0.016
  34. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine. Cancer Treat Rep. 1978 Apr; 62(4):567-9.
    View in: PubMed
    Score: 0.015
  35. Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1978 Mar; 62(3):327-32.
    View in: PubMed
    Score: 0.015
  36. Clinicopathologic correlations demonstrating the failure of 67gallium scanning in determining response to radiotherapy. Chest. 1978 Mar; 73(3):356-9.
    View in: PubMed
    Score: 0.015
  37. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin Oncol. 1998 Feb; 25(1 Suppl 2):8-14.
    View in: PubMed
    Score: 0.015
  38. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
    View in: PubMed
    Score: 0.015
  39. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J Clin Oncol. 1997 Mar; 15(3):884-92.
    View in: PubMed
    Score: 0.014
  40. Adriamycin-radiotherapy interaction. Ann Intern Med. 1977 Jan; 86(1):117.
    View in: PubMed
    Score: 0.014
  41. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1976 Sep; 60(9):1225-30.
    View in: PubMed
    Score: 0.014
  42. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Semin Oncol. 1996 Jun; 23(3 Suppl 6):11-5.
    View in: PubMed
    Score: 0.014
  43. Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. Semin Oncol. 1996 Jun; 23(3 Suppl 7):15-8.
    View in: PubMed
    Score: 0.014
  44. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Semin Oncol. 1996 Apr; 23(2 Suppl 5):11-8.
    View in: PubMed
    Score: 0.013
  45. Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. Ann Oncol. 1996 Mar; 7(3):314-6.
    View in: PubMed
    Score: 0.013
  46. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):288-94.
    View in: PubMed
    Score: 0.013
  47. Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):38-41.
    View in: PubMed
    Score: 0.013
  48. Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 5):30-7; discussion 41-4.
    View in: PubMed
    Score: 0.013
  49. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
    View in: PubMed
    Score: 0.012
  50. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
    View in: PubMed
    Score: 0.007
  51. Use and prognostic value of staging mediastinoscopy in non-small-cell lung cancer. Surgery. 1987 Oct; 102(4):652-9.
    View in: PubMed
    Score: 0.007
  52. Pleural involvement in stage IIIM0 non-small-cell bronchogenic carcinoma. A need to differentiate subtypes. Am J Clin Oncol. 1986 Jun; 9(3):255-61.
    View in: PubMed
    Score: 0.007
  53. Regional accuracy of computed tomography of the mediastinum in staging of lung cancer. J Thorac Cardiovasc Surg. 1986 Apr; 91(4):498-504.
    View in: PubMed
    Score: 0.007
  54. The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 1986 Mar; 91(3):344-9.
    View in: PubMed
    Score: 0.007
  55. Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report. Cancer. 1986 Jan 01; 57(1):44-53.
    View in: PubMed
    Score: 0.007
  56. CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma. A 7-year experience (1975-1981) with 160 patients. Cancer. 1985 Nov 15; 56(10):2385-90.
    View in: PubMed
    Score: 0.007
  57. Large cell carcinoma of the lung. Ultrastructural differentiation and clinicopathologic correlations. Cancer. 1985 Oct 01; 56(7):1618-23.
    View in: PubMed
    Score: 0.006
  58. Second malignancies in hairy cell leukemia. Cancer. 1985 Sep 15; 56(6):1462-7.
    View in: PubMed
    Score: 0.006
  59. Malignant superior vena cava obstruction reconsidered: the role of diagnostic surgical intervention. Ann Thorac Surg. 1985 Sep; 40(3):285-8.
    View in: PubMed
    Score: 0.006
  60. Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience. Cancer. 1984 Jul 01; 54(1):5-12.
    View in: PubMed
    Score: 0.006
  61. Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1984 Feb; 68(2):413-5.
    View in: PubMed
    Score: 0.006
  62. The use of serum albumin for further classification of Stage III non-oat cell lung cancer and its therapeutic implications. Ann Thorac Surg. 1984 Feb; 37(2):115-22.
    View in: PubMed
    Score: 0.006
  63. Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach. J Thorac Cardiovasc Surg. 1983 Aug; 86(2):180-5.
    View in: PubMed
    Score: 0.006
  64. Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy. Eur J Cancer Clin Oncol. 1983 Jan; 19(1):33-8.
    View in: PubMed
    Score: 0.005
  65. Prognostic factors in patients with non-small cell bronchogenic carcinoma and brain metastases. Cancer. 1982 May 01; 49(9):1916-9.
    View in: PubMed
    Score: 0.005
  66. Bronchogenic carcinoma located in the aortic window. The importance of the primary lesion as a determinant of survival. J Thorac Cardiovasc Surg. 1982 Apr; 83(4):551-62.
    View in: PubMed
    Score: 0.005
  67. VP16-213 in combined modality treatment of small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1982 Apr; 18(4):343-6.
    View in: PubMed
    Score: 0.005
  68. Prognostic significance of immunological tests in lung cancer. Clin Exp Immunol. 1981 Feb; 43(2):362-9.
    View in: PubMed
    Score: 0.005
  69. Small-cell carcinoma of the lung: a five-year experience with combined modality therapy. Cancer. 1980 Dec 15; 46(12):2550-6.
    View in: PubMed
    Score: 0.005
  70. Clinical value of quantitative ventilation-perfusion lung scans in the surgical management of bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1980 Oct; 80(4):535-43.
    View in: PubMed
    Score: 0.005
  71. The non-Hodgkin lymphomas. Curr Probl Cancer. 1980 Jan; 4(7):1-35.
    View in: PubMed
    Score: 0.004
  72. Sequential staging in bronchogenic carcinoma. Chest. 1979 Dec; 76(6):653-7.
    View in: PubMed
    Score: 0.004
  73. The role of gallium-67 scanning in the clinical staging and preoperative evaluation of patients with carcinoma of the lung. Ann Thorac Surg. 1979 Nov; 28(5):451-64.
    View in: PubMed
    Score: 0.004
  74. The relationship between immune reactivity, serum cortisol, and stage of disease in patients with non-oat-cell bronchogenic carcinoma. Surgery. 1979 Jul; 86(1):130-7.
    View in: PubMed
    Score: 0.004
  75. Gallium-67 scanning for carcinoma of the lung. J Thorac Cardiovasc Surg. 1976 Nov; 72(5):699-708.
    View in: PubMed
    Score: 0.003
  76. Letter: Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC-26271), vincristine (NSC-67574), and methotrexate (NSC-7040). Cancer Treat Rep. 1976 Mar; 60(3):221-3.
    View in: PubMed
    Score: 0.003
  77. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981 Oct; 58(4):759-67.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.